Kalle Mattila
kalmat@utu.fi |
Publications
- Survival of Women Previously Diagnosed of Melanoma with Subsequent Pregnancy: A Systematic Review and Meta-Analysis and a Single-Center Experience (2022)
- Journal of Clinical Medicine
(A2 Refereed review article in a scientific journal ) - Tutkijalähtöinen kliininen lääketutkimus syöpäpotilailla - miten pystytän ja hoidan (2022)
- Duodecim
(D1 Article in a professional journal) - Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study (2022)
- Cancer Biotherapy and Radiopharmaceuticals
(A1 Refereed original research article in a scientific journal) - A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinomaKinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer (2021)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - Ihomelanooman onkologinen hoito päivittyi (2021)
- Duodecim
(A2 Refereed review article in a scientific journal ) - (2021)
- ESMO OpenLääkärilehti
(A1 Refereed original research article in a scientific journal) - Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha (2021)
- Melanoma ResearchAnticancer Research
(A1 Refereed original research article in a scientific journal) - (2021)
- European Journal of Nuclear Medicine and Molecular Imaging
(A1 Refereed original research article in a scientific journal) - Syöpälääkkeiden aiheuttamat iho-ongelmat (2021)
- Lääkärilehti
(A2 Refereed review article in a scientific journal ) - Uudet immunologiset syöpälääkkeet ja niiden turvallinen käyttö syöpäpotilaiden hoidossa (2021)
- Syöpäsairaanhoitaja
(D1 Article in a professional journal) - Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma (2019)
- Acta Oncologica
(B1 Non-refereed article in a scientific journal) - Immuno-onkologisten lääkkeiden käyttö, haittavaikutukset ja niiden hoito (2019)
- Duodecim
(A2 Refereed review article in a scientific journal ) - Immuuniaktivaation vapauttajien haittavaikutukset : miten tunnistan ja hoidan? (2018)
(D1 Article in a professional journal) - (2018)
(A1 Refereed original research article in a scientific journal)



